Fiber Mix & Glycemic Response

Status Completed

Clinical Trial Summary

This study determines the acute effect of a dietary fiber mix on blood glucose levels. Participants will consume the fiber mix as a drink and we will monitor changes in blood glucose levels. All participants will consume white bread as the control food.

Clinical Trial Description

There is some evidence for increased dietary fiber intake to positively impact on metabolic outcomes in patients with type 2 diabetes, potentially via modulating gut microbial composition and functions. We have developed a dietary fiber mix that is consisted of fiber of various physicochemical properties to maximize the fermentability of the supplement and thus its effects on the gut microbiota. Since the fiber mix also contains nutrients that will raise blood glucose levels, we need to characterize the glycemic response to the fiber mix itself, before we can use it in an upcoming trial to determine the effect of dietary fiber supplementation on the gut microbiota and glycemic control.

Enrolled participants will be assigned to a subject group based on their diagnosis of type 2 diabetes and fasting blood glucose concentrations. Participants who are clinically diagnosed with impaired glucose tolerance or type 2 diabetes will be assigned to the Prediabetes/Diabetes group. For the other participants, those with fasting blood glucose < 100 mg/dL will be assigned to the Non-Diabetes group, and those with fasting blood glucose > 100 mg/dL will be assigned to the Prediabetes/Diabetes group.

Participants will attend 8 food testing visits over 2 weeks. For each visit, participants will attend the research facility in the morning after an overnight fast. They will consume either white bread (with 50 g of available carbohydrates as a control food) or 60 g of the fiber mix (as a drink).

Postprandial glycemic response will be assessed by changes in blood glucose levels, to be monitored using a continuous glucose monitoring system (FreeStyle Pro). A sensor will be placed on the participant's arm and will stay on until the end of the study.

Participants will provide photos of all the food and drink and a brief description of what they have consumed throughout the 2-week study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03334643
Study type	Interventional
Source	Rutgers, The State University of New Jersey
Contact
Status	Completed
Phase	N/A
Start date	June 4, 2018
Completion date	February 1, 2019

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04082091` - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Active, not recruiting	`NCT02248311` - "Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population	N/A
Completed	`NCT02653300` - A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)	Phase 2
Completed	`NCT03655535` - Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes	Phase 2
Completed	`NCT03256747` - Effects of Neuromuscular Electrical Stimulation on Glucose Variability in Patients With Type 2 Diabetes	N/A
Withdrawn	`NCT03675074` - Neujia Anastomosis for Treatment of Obesity and Type II Diabetes	N/A
Completed	`NCT05343767` - Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus	N/A
Withdrawn	`NCT03190798` - Effects of Canagliflozin on Intravascular Volume and Hemodynamics	Phase 4
Withdrawn	`NCT03437330` - Empagliflozin Effect on Glucose Toxicity	Phase 4
Withdrawn	`NCT03008395` - Empowerment, Motivation and Medical Adherence (EMMA).	N/A
Not yet recruiting	`NCT05539066` - AI Health Assistant and Type 2 Diabetes	N/A
Completed	`NCT03682445` - Metabolic, Physical Responses To Exercise In Patients With Type 2 Diabetes Mellitus	N/A
Not yet recruiting	`NCT03239119` - The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus	Phase 3
Completed	`NCT03259789` - Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects	Phase 3
Recruiting	`NCT03506230` - Financial Incentives for Low Socioeconomic Diabetic Patients	N/A
Completed	`NCT03072407` - MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM	Phase 1
Completed	`NCT05668442` - Feasibility of an Online Exercise Community Among Individuals With Type 2 Diabetes
Completed	`NCT02964572` - Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes	N/A
Completed	`NCT02956044` - Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin	Phase 1
Completed	`NCT02628392` - A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Fiber Mix and Glycemic Response

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms